The Valley Desk

ArticleAJNR. American journal of neuroradiologyPublished

Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801)

Read the publication ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Perelman School of Medicine, University of Pennsylvania. Affiliation source

Publication record

Type
Article
Venue
AJNR. American journal of neuroradiology
Published
PubMed ID
42217836
Added to directory
Source checked

Report a correction or request removal